Navigation Links
Ambry Genetics Becomes First Certified Service Provider in US for NimbleGen SeqCap EZ Exome
Date:9/9/2010

ALISO VIEJO, Calif., Sept. 9 /PRNewswire/ -- Roche NimbleGen (SIX: RO, ROG; Pink Sheets: RHHBY) announces that Southern California (Aliso Viejo) based genomic services provider Ambry Genetics has officially become a Certified Service Provider (CSP) for the NimbleGen SeqCap EZ Exome workflow. They will provide target-enrichment services using NimbleGen SeqCap EZ Human Exome coupled with next-generation sequencing services for genetic research. Ambry Genetics has passed a rigorous certification test plan with precise experimental standards to officially join the Roche NimbleGen Certified Service Provider Program. They will process customer gDNA samples for genomic enrichment, using 2.1 million optimized DNA probes from SeqCap EZ Exome to capture all human coding exons, and sequence the enriched samples using short-read, paired-end sequencing.

(Logo:  http://photos.prnewswire.com/prnh/20090428/LA06744LOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20090428/LA06744LOGO)

“Our Genomics team has processed hundreds of samples for various projects utilizing many target-enrichment technologies. Ambry Genetics is very honored to have been selected by Roche NimbleGen as the first Certified Service Provider in the United States offering the NimbleGen SeqCap EZ Human Exome product. With this addition, we are currently the only service provider in the world to offer the latest in sequence capture technologies to researchers,“ said Ardy Arianpour, Vice President of Business Development at Ambry Genetics.

“Roche NimbleGen is extremely excited to welcome Ambry Genetics as our first Certified Service Provider in the United States. This addition will provide more researchers with access to the innovative NimbleGen SeqCap EZ Human Exome technology. Ambry Genetics’ commitment to high quality genomic and next-generation sequencing services is an ideal fit with our SeqCap EZ Exome technology, and we look forward to this partnership and the innovation and value it will provide to the research market" said Dr. Frank Pitzer, CEO of Roche NimbleGen, Inc.  

For more information about Roche NimbleGen, please visit www.nimblegen.com

About Ambry Genetics

Ambry Genetics is a CAP-accredited, CLIA-certified commercial clinical laboratory headquartered in Aliso Viejo, California. Established in 2000, it is a recognized leader in diagnostic and contract genomic services. Ambry specializes in the application of new technologies to molecular diagnostics and genetics research. To learn more about Ambry Genetics, visit www.ambrygen.com

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2008, Roche had over 80,000 employees worldwide and invested almost 9 billion Swiss francs in R&D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

For life science research only. Not for use in diagnostic procedures.  NIMBLEGEN and SEQCAP are trademarks of Roche.

Other brands or product names are trademarks of their respective holders.


'/>"/>
SOURCE Ambry Genetics; Roche NimbleGen
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ambry Genetics Announces the Addition of Illumina HiSeq 2000 and First 510(K) Approved BeadXpress® to Its Sequencing and Genotyping Capabilities
2. Ambry Genetics Introduces AmbryScreen(TM), a Genetic Test Screening for Some of the Most Common and Severe Genetic Disorders Affecting Newborns.
3. Ambry Genetics and RainDance Technologies Announce Partnership for Diagnostics and Genomics Services Utilizing the RDT 1000 for Sequence Enrichment and Targeted Resequencing Validation
4. Ambry Genetics Announces Launch of Their StemArray(TM) Product and Services for High Resolution Characterization of Human Stem Cells
5. Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects
6. Reportlinker Adds Epigenetics: Current and future applications that are driving novel drug discovery
7. Interleukin Genetics Moves Trading of Stock to OTCQB Marketplace
8. Interleukin Genetics, Inc. Announces Conference Call to Discuss Second Quarter 2010 Results
9. China Medical Technologies Announces the Recent Publication of a Study on its SPR Analyzer and HPV DNA Chip in Cancer Genetics and Cytogenetics and the Creation of a Medical Publications Column to the Investor Relations Section on its Website
10. London Genetics Conference Proceedings Published in Drug Discovery Today
11. Interleukin Genetics, Inc. Announces Conference Call to Discuss First Quarter 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... the largest share of the market in 2016 and ... dominance can be attributed to a large number of ... (US hold the largest share in the patient temperature ... benefits such as reducing loss of blood during surgeries, ...
(Date:12/8/2016)... 8, 2016 Research and Markets has announced ... Trends - Adhesion Type, Application, Usability - Forecast to 2025" ... , ... Market is poised to grow at a CAGR of around 3.2% ... market is witnessing include advancements in extracellular microelectrode arrays and intracellular ...
(Date:12/8/2016)... Quebec , Dec. 8, 2016  Valeant ... and TSX: VRX) ("Valeant") today announced positive results ... clinical study to assess the safety and efficacy ... the treatment of plaque psoriasis. ... subjects with moderate to severe psoriasis, IDP-118 showed ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... MEDI+SIGN®, a provider ... that a new solution for Emergency Departments (ED) has been added to their ... Emergency Department examination rooms, and with a simplified pallet of information available to ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... with distinction by the Undersea and Hyperbaric Medical Society (UHMS), the leading authority ... care and patient safety. Only a few hospitals and facilities have earned this ...
(Date:12/8/2016)... ... December 08, 2016 , ... Seavest ... Property owned by an affiliate of Seavest, has won a prestigious national healthcare ... Chester County ambulatory care center (ACC) was named “Best New Development, MOBs and ...
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman , ... Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont ... and attorneys from the firm’s global Life Sciences & Medical Technology Group have been ...
(Date:12/8/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it had joined the Pharmaceutical Supply Chain Initiative (PSCI). ... unite pharmaceutical and healthcare companies that share a vision of better, social, environmental ...
Breaking Medicine News(10 mins):